CareDx, Inc. reports developments in precision medicine for transplant patients and caregivers. The company’s updates center on non-invasive molecular testing for heart, kidney, and lung transplantation, including AlloSure, AlloMap, HeartCare, and related evidence generation for post-transplant surveillance, risk assessment, and longitudinal patient management.
CareDx news also covers operating and financial results for testing services and patient and digital solutions, product and platform launches such as VANTx clinical data analytics, clinical conference presentations, material agreements, and Nasdaq-related governance matters including inducement equity awards.
CareDx (CDNA) announced publication of its third KOAR analysis, linking early AlloSure Kidney measurement patterns with three-year kidney transplant outcomes.
The analysis in Transplantation covered 1,137 recipients across 56 centers, grouping measurements of donor-derived cell-free DNA, a molecular marker, during the first four months after transplant. Persistent elevation was associated with a nine-fold higher incidence of graft loss than consistently low levels. Late elevation was independently associated with donor-specific antibody development, rejection and graft loss; 8.8% of that group experienced graft loss. Transient elevations that resolved were not associated with worse outcomes. Most recipients, 83.7%, had consistently low levels and favorable three-year outcomes.
CareDx (Nasdaq: CDNA) reported third-quarter 2026 revenue of $139 million, up 39% from the same period last year. GAAP net income reached $19.292 million versus $1.675 million, with diluted earnings per share of $0.35 versus $0.03. Adjusted EBITDA rose to $30 million from $15 million.
Testing Services revenue grew 65% to $119 million, including $12 million from Specialty Oncology and $15 million recognized for prior-period tests. Patient and Digital Solutions revenue increased 31% to $20 million. CareDx raised its 2026 revenue outlook to $520 million–$530 million and adjusted EBITDA outlook to $90 million–$100 million. It completed the Naveris acquisition on July 1 for $160 million cash plus up to $100 million in contingent consideration. CareDx plans an AlloHeme launch in the first quarter of 2027 and broader HistoMap Kidney availability in 2027.
CareDx (CDNA) highlighted AlloSure Kidney study results addressing transplant risk assessment, biopsy use and rejection prediction at ASN Kidney Week 2026.
In 131 recipients with borderline changes or T-cell-mediated rejection, AlloSure levels ≥1% were independently associated with nearly 3-fold higher risk of graft loss or ≥30% kidney-function decline (P=0.002). An independent randomized trial of 332 recipients found 49% fewer biopsies with donor-derived cell-free DNA monitoring during months 3–12, with similar safety outcomes. A validation study of 4,976 recipients and 6,827 biopsies found AlloSure Kidney and AlloSure Plus maintained rejection prediction under updated Banff 2024 pathology criteria, with an AUC of 0.833, a measure of predictive discrimination.
CareDx (CDNA) will report third-quarter 2026 financial results after market close on October 29, 2026, and host a conference call that day.
The call and webcast will begin at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast will be available in the Events & Presentations section of the company’s investor relations website.
CareDx (Nasdaq: CDNA) announced that on August 5, 2026 it granted inducement restricted stock units (RSUs) to 35 new employees under its 2025 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4). The awards cover an aggregate of 97,090 shares of common stock.
For 34 employees, a total of 93,090 RSUs vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remainder in equal quarterly installments, subject to continued service. For one employee, 4,000 RSUs vest in full on the first anniversary, also subject to continued service.
CareDx (Nasdaq: CDNA) announced that on July 30, 2026, it granted inducement equity awards to James McNally, the company’s newly appointed Executive Advisor. The award consists of 15,822 restricted stock units (RSUs) of CareDx common stock, granted as a material inducement to his employment.
According to CareDx, the RSUs were issued under the company’s 2025 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). 50% of the RSUs are scheduled to vest on January 2, 2027 and the remaining 50% on July 2, 2027, subject to Mr. McNally’s continued service with CareDx through each vesting date.
CareDx (Nasdaq: CDNA) reported Q2 2026 revenue of $132 million, up 52% year-over-year, driven by Testing Services revenue of $100 million (+61%) on approximately 58,000 tests (+17%), Patient and Digital Solutions revenue of $19 million (+50%), and Lab Product revenue of $13 million (+8%).
According to CareDx, Q2 GAAP net income was $111 million versus a $9 million loss a year ago, including a $113 million gain on the June 30 sale of its Lab Products business to Eurobio Scientific. Non-GAAP net income was $20 million and adjusted EBITDA was $25 million versus $5 million in Q2 2025. The company raised 2026 revenue guidance to $490–$500 million (from $447–$465 million) and adjusted EBITDA guidance to $66–$78 million (from $43–$57 million). As of June 30, 2026, CareDx reported cash and cash equivalents of $374 million and stockholders’ equity of $426 million.
CareDx (Nasdaq: CDNA) announced it will report its second quarter 2026 financial results after market close on Thursday, July 30, 2026. The company will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET, with live and archived access available through the Events & Presentations section of its investor relations website.
CareDx (Nasdaq: CDNA) announced finalization of a Medicare Local Coverage Determination (LCD) for molecular testing used to detect solid organ allograft rejection in kidney, heart, and lung transplants. The final policy affirms and maintains coverage across CareDx’s transplant surveillance portfolio.
For AlloSure Kidney, Medicare will cover up to six surveillance tests in the first year post‑transplant and up to four tests per year in years two and three, with for‑cause testing unchanged. For AlloMap and AlloSure Heart, coverage is maintained, including combination use, with up to 12 surveillance tests in year one and four in years two and three. AlloSure Lung coverage is also maintained with up to 12 tests in the first year and four in years two and three. The Final LCD was published on July 16, 2026, and is expected to take effect on August 30, 2026.
CareDx (Nasdaq: CDNA) completed its acquisition of Naveris, adding the NavDx blood-based test for HPV-driven head and neck and anal cancers to its portfolio. NavDx is the first and only Medicare-covered MRD assay in these indications, with an ADLT Medicare rate of $1,800 and over 130,000 tests reported.
Naveris generated about $35 million revenue in 2025, more than doubling year-over-year. The deal expands CareDx’s estimated U.S. addressable market to over $12 billion across transplant, specialty oncology, and cell therapy. Naveris will be included in CareDx’s consolidated financial results beginning in Q3 2026.